ADAR1 Capital Management, LLC and Daniel Schneeberger filed a Form 4 on November 9, 2026, disclosing a purchase of 2,640 common shares of InMed Pharmaceuticals Inc. (now Mentari Therapeutics, Inc.) on November 5, 2026, at a weighted average price of $13.0953 per share.
Key Highlights
- Purchase transaction: 2,640 common shares acquired on November 5, 2026, with transaction code P (purchase).
- Weighted average price: $13.0953 per share, with individual transactions ranging from $12.9500 to $13.3000, inclusive.
- Post-transaction beneficial ownership: 98,297 common shares beneficially owned following the reported transaction, held indirectly through private investment funds managed by ADAR1 Capital Management, LLC.
- Reverse stock split: On November 4, 2026, the issuer effected a 1-for-10 reverse stock split of its outstanding common stock; the reported transaction occurred after giving effect to that split.
- Merger and name change: On November 6, 2026, the issuer completed a previously announced merger and changed its name from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc., and its trading symbol from INM to MTRI.
- Section 16 status: Following completion of the merger and related transactions, the reporting persons disclosed they ceased to beneficially own more than 10% of the issuer's outstanding common stock and stated they "are no longer subject to Section 16."
ADAR1 Capital and Schneeberger Report November 5 Purchase Amid Merger Completion
According to the filing, ADAR1 Capital Management, LLC and Daniel Schneeberger, its sole manager, jointly filed this Form 4 as 10% owners of InMed Pharmaceuticals Inc., now operating as Mentari Therapeutics, Inc. (NASDAQ:MTRI). The reported transaction is a purchase of 2,640 common shares on November 5, 2026, at a weighted average price of $13.0953. The filing notes the shares were acquired in multiple transactions at prices ranging from $12.9500 to $13.3000, inclusive, and that full detail on shares purchased at each separate price is available upon request to the issuer, any security holder, or SEC staff.
The filing discloses that on November 4, 2026, the issuer effected a 1-for-10 reverse stock split of its outstanding common stock, and the transaction reported herein occurred on November 5, 2026, after giving effect to that split. Following the November 6, 2026 merger completion, the issuer changed its name from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc. and its trading symbol from INM to MTRI. The filing states that after the merger and related transactions, the reporting persons ceased to beneficially own more than 10% of the issuer's outstanding common stock.
The 98,297 shares beneficially owned following the transaction are held indirectly through private investment funds managed by ADAR1 Capital Management, LLC. The filing includes a disclaimer noting that each reporting person "disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any," and states that the report shall not be deemed an admission of beneficial ownership for Section 16 or other purposes.
What Was Disclosed
ADAR1 Capital Management, LLC and Daniel Schneeberger reported a purchase of 2,640 common shares at a weighted average of $13.0953 on November 5, 2026, leaving indirect beneficial ownership of 98,297 shares following the transaction and a completed merger that renamed the issuer Mentari Therapeutics, Inc.




Please wait processing your request...